CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era

Am J Med. 2024 May;137(5):390-392. doi: 10.1016/j.amjmed.2023.12.018. Epub 2024 Jan 4.

Authors

Eli Y Adashi¹, Philip A Gruppuso², I Glenn Cohen³

Affiliations

¹ Department of Medical Science, Warren Alpert Medical School, Brown University, Providence, RI. Electronic address: Eli_Adashi@brown.edu.
² Department of Medical Science, Warren Alpert Medical School, Brown University, Providence, RI.
³ Harvard Law School, Faculty Director, Harvard University, Cambridge, Mass; Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge, Mass.

PMID: 38184185
DOI: 10.1016/j.amjmed.2023.12.018

No abstract available

Publication types

Editorial

MeSH terms

Anemia, Sickle Cell* / genetics
Anemia, Sickle Cell* / therapy
CRISPR-Cas Systems*
Gene Editing* / methods
Genetic Therapy* / methods
Humans